Trump Announces Drug Cost Reduction Deal with Regeneron
On April 23, 2026, President Donald Trump revealed a significant agreement with Regeneron Pharmaceuticals aimed at lowering drug prices. This initiative is a key part of the administration’s broader effort to tackle drug pricing, which has been a major focus during his presidency.
According to the announcement, Regeneron will lower prices for its medications, including those released in the future under Medicaid. Notably, the cholesterol medication Praluent will be offered at $225 through the TrumpRx discount platform, as detailed in a White House fact sheet.
“This should be front page news,” Trump stated while discussing the deal. He remarked, “We have to win in the midterm elections, and unfortunately, that’s not going to happen.”
The timing of this agreement is interesting, as it comes ahead of the November midterm elections, with the administration focusing on economic relief. This response seems to address the financial pressures that rising healthcare, fuel, and food costs are placing on American families.
It’s worth noting that Regeneron is the final company among 17 major drug manufacturers to reach an agreement with the administration after Trump sent letters last July urging that U.S. drug prices be aligned with those in other developed nations.
This partnership holds personal significance for Trump, especially considering his past with Regeneron. During his hospitalization for COVID-19 in 2020, he was treated with an experimental antibody cocktail from the company and later praised its effectiveness in a public video.
Beyond price reductions, the White House has also announced that Regeneron will invest $27 billion in domestic research, development, and manufacturing. Such commitments often help companies obtain relief from administrative tariffs, aligning with the president’s “America First” strategy.
Coincidentally, this announcement follows the FDA’s recent approval of Regeneron’s gene therapy drug Otalmeni, designed to restore hearing for certain patients. The company celebrated this milestone on social media, heralding advances in hearing health.
